Расширенный поиск


Полный текст:

Об авторе

А. Ж. Карабаева
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
кафедра нефрологии и диализа факультета последипломного обучения

Список литературы

1. Foster RH, MacFarlane CH, Bustamante MO. Recent progress in understanding aldosterone secretion. Gen Pharmacol1997; 28: 647-651

2. Fuller PJ. Aldosterone’s effects and mechanism of action. Curr Opin Endocrinol Diabetes 1997; 4: 218-224

3. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell1998; 93: 487-490

4. Helman SI, Liu X, Baldwin K et al. Time-dependent stimulation by aldosterone of blocker-sensitive ENaCs in A6 epithelia. Am J Physiol Cell Physiol1998; 274: C 947-C 957

5. Booth E, Johnson JP, Stockand JD. Aldosterone. Adv Physiol Educ2002; 26: 8-20

6. Rossier BC. Mechanisms of action of mineralocorticoid hormones. Endocr Res1989; 15: 206-226

7. Duprez D, de Buyzere M, Rietzchel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep2000; 2; 327-334

8. Wehling M. Nongenomic actions of steroid hormones. Trends Endocrinol Metab 1994; 5: 347-353

9. Wehling M, Spes CH, Win N et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517-3522

10. Christ M, Douwes K, Eisen C et al. Rapid nongenomic effects of aldosterone on sodium transport in rat vascular smooth muscle cells: involvement of the Na +/H + antiport. Hypertension 1995; 25: 117-123

11. Wehling M, Neylon CB, Fullerton M et al. Nongenomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res 1995; 76: 973-979

12. Ebata S, Muto S, Okada K et al. Aldosterone activates Na+/H + exchange in vascular smooth muscle cells by non-genomic and genomic mechanisms. Kidney Int 1999; 56: 1400-1412

13. Gekle M, Freudinger R, Mildenberger S, Silbernagl S. Rapid actions of aldosterone on cells from renal epithelium: the possible role of EGF-receptor signaling. Steroids 2002; 67: 499–504

14. Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transpl2003; 18: 1984-1992

15. Silvestre JS, Heymes C, Oubenaisso A et al. Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-2701

16. Stier Jr CT, Benter IF, Ahmad S et al. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension1989; 13:115–121

17. Stier Jr CT, Chander PN, Gutstein WH et al. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens1991; 4: 680 – 687

18. Weber KT. Aldosterone in congestive hear failure. N Engl J Med2001; 345 1689 – 1697

19. Camargo MJ, von Lutterotti N, Campbell Jr WG et al. Control of blood pressure and end-organ damage in maturing saltloaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens1993; 11: 31–40

20. Stier Jr CT, Adler LA, Levine S, Chander PN. Stroke prevention by losartan in troke-prone spontaneously hypertensive rats. J Hypertens 1993; 11 [Suppl 3]: S37–S42

21. Jalil JE, Janicki JS, Pick R, Weber KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J ypertens 1991; 4: 51–55

22. Laragh JH, Sealy JE. The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar constriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Laragh JH, Brenner BM (eds) Hypertension 1990; Pathophysiology, Diagnosis, and Management. Raven Press, New York, 1329–1348

23. Rossi GP, Sachetto A, Visentin P et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039–1045

24. Halimi JM, Mimram A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995; 13: 1801–1802

25. Takeda R, Matsubara T, Miyamori I et al. Research Committee of Disorders of Adrenal Hormones in Japan. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. J Endocrinol Invest 1995; 18: 370–373

26. Nishimura M, Uzu T, Fuji T et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261–266

27. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717

28. Oberleithner H, Ludwig T, Riethmuller C et al. Human endothelium: target for aldosterone. Hypertension 2004; 43 (5): 952-957

29. Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in glomerular microcirculation. J Am Soc Nephrol 2003; 14 (9): 2255-2253

30. Todd-Turla KM, Schnermann J, Fejes-Toth G et al. Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron. Am J Physiol 1993; 264 (5, Pt 2): F 781-F 789

31. Komel L. Colocalisation of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994; 7 (2): 100-103

32. Jucknevicius I, Segal Y, Kren S et al. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol 2004; 286 (6): F 1059-F 1062

33. Krug AW, Grossmann C, Schuster C et al. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem 2003; 278 (44): 4360-4366

34. Wehling M. Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. J Mol Med 1995; 73: 439-447

35. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol 2002; 283 (20): F 209-F 223

36. Lai LJ, Gu Y, Chen J et al. Production of aldosterone by rat mesangial cell and accumulation of extracellular matrix induced by aldosterone. Zhounghua Yi Xu 2003; 83 (21): 1900-1905

37. Nishiyama A, Abe Y. Aldosterone and renal injury. Folia Pharmacol Jap2004; 124 (2): 101-109

38. Epstein M. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications.Am J Kidney Dis 2001; 37: 677-688

39. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest1986; 77: 1993-2000

40. Ritz E, Orth S, Weinreich T, Wagner J. Systemic hypertension versus intraglomerular hypertension in progression. Kidney Int1994; 45: 438-442

41. Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int1987; 31: 752-759

42. The GISEN Study Group: Randomized placebo-controlled trial of effect of ramipril on decline in GFR and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. The GISEN Group. Lancet1997; 349: 1857-1863

43. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462

44. Greene E, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068

45. Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int1978; 14: 228-235

46. Hene RJ, Boer P, Koomans HA, Dorhout Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101

47. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41: 326-333

48. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159-172

49. Rovner DR, Conn JW, Knopf RF et al. Nature of renal escape from the sodiumretaining effect of aldosterone in primary aldosteronism and in normal subjects. J Clin Endocrinol Metab1965; 25: 53-64

50. Rocha R, Chander PN, Khanna K et al. Mineralocorticoid blokade reduces vascular injury in strokeprone hypertensive rats. Hypertension 1998; 31: 451-458

51. Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85: 336-344

52. Brown NJ, Nakamura S, Ma L et al. Aldosterone stimulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227

53. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factorbeta 1 in renal fibrosis of rats. Hypertension 2000; 35: 1078-1084

54. Кузьмин ОБ, Пугаева МО, Бучнева НВ. Блокада почечных минералкортикоидных рецепторов: новый подход к нефропротективной терапии гипертензивных больных с хронической болезнью почек. Нефрология 2005; 9 (1) 19-24

55. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583

56. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in prevenring myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16A

57. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II reseptors in the rat. Can J Physiol Pharmacol 1985; 63: 1522-1527

58. Weber KT, Anversa P, Armstrong PW et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992; 20: 316

59. Rocha R, MartinBerger CL, Yang P et al. Selective aldosterone blockade prevents angiotensin II/saltinduced vascular inflammation in the rat heart. Endocrinology2002; 143: 4828-4836

60. Brown NJ, Vaughan DE, Fogo AB. The reninangiotensin aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol2002; 22: 399-406

61. Brown NJ, Agirbasli MA, Williams GH et al. Effect of activation and inhibition of the reninangiotensin system on plasma PAII. Hypertension 1998; 32: 965-971

62. Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI – 1: implications for renal injury. J Nephrol 2002; 15 (3): 230-235

63. Weber К.Т., Brilla С.G. Pathological hypertrophy and cardiac interstitium: fibrosis and reninangiotensinaldosterone system. Circulation 1991; 83: 1849-1865

64. Weber К.Т., Brilla С.G., Camphell S.E. et al. Pathological hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Pressure1992, 1: 75-85

65. Jeunemaitre X, Chatellier G, KreftJais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-825

66. de Gasparo M, Whitebread SE, Preiswerk G et al. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989; 32: 223-227

67. Delyani J, Myles K, Funder J et al. Eplerenone (SC 66110), a highly selective aldosterone antagonist. Am J Hypertens1998; 11: 94A.

68. Rocha R, Chander P, Zuckerman A et al. Role of mineralocorticoids in renal injury in strokeprone hypertensive rats. Hypertension1998; 32: 598

69. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int2003; 63: 1791-1800

70. Lacolley P, Labat C, Pujol A et al. Increased carotid wall elastic modulus and fibronectin in aldosteronesalttreated rats: effects of eplerenone. Circulation2002; 106: 2848-2853

71. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol2002; 83: H 1802-1810

72. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol2001; 281: H647-654

73. Rajagopalan S, Duquaine D, King S et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212-2226

74. Ward M, Kanellakis P, Ramsey D. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104: 467-472

75. Suzuki G, Morita H, Mishima T, et al. Effects of long term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002; 106: 2967-72

76. Pitt B, Remme W, Zannad F et al. for the Eplerenone PostAcute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321

77. Epstein M, Alexander JC, Roniker B. Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension. Hypertension 1999; 33: 1075

78. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mildto moderate hypertension. Am J Hypertens 2002; 15: 709-716

79. Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renninangiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-123

80. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension2005; 46: 1227-1246

Для цитирования:

Карабаева А.Ж. АЛЬДОСТЕРОН, СЕРДЕЧНО-СОСУДИСТАЯ СИСТЕМА И ПОЧКИ. Нефрология. 2006;10(1):25-34.

For citation:

Karabaeva A.Z. ALDOSTERONE, CARDIOVASCULAR SYSTEM AND KIDNEYS. Nephrology (Saint-Petersburg). 2006;10(1):25-34. (In Russ.)

Просмотров: 106

ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)